Cytiva and Pall to spend $1.5bn on manufacturing capacity expansion, new hires

By Jane Byrne contact

- Last updated on GMT

© GettyImages/Colin Anderson Productions pty ltd
© GettyImages/Colin Anderson Productions pty ltd

Related tags: Pall, Cytiva, chromatography resins, Cell culture media, single-use technologies

Cytiva and Pall Corporation, both subsidiaries of Danaher Corporation, have announced they are to invest US$1.5bn to expand manufacturing capacity across 13 sites globally

The investment will include the doubling of capacity in multiple site locations as well as two new sites: one in the UK and one in the US.

This is the largest investment in capacity to date for Pall and Cytiva, following five acquisitions made by the companies this year and an additional US$500m in previously-announced investments.

The life sciences focused duo also plan to hire around 2,000 new employees over the next two years two support growth.

This investment, continued the companies, also looks to address some of the key challenges highlighted in the Global Biopharma Resilience Index​, conducted by Longitude, a Financial Times​ company, and published by Cytiva in March 2021, including hiring and training talent, R&D collaboration, supply chain resilience, manufacturing models, as well as government policy and regulation.

Where the money will go

The capacity expansion will increase the manufacture of key products used to make biologic medicines. The companies are investing:

  • US$600m+ in chromatography resins – media for analyzing or purifying biomolecules – establishing a new manufacturing site in the US.
  • US$400m+ in cell culture media – in liquid or powder form this is used to grow and cultivate cells before they are purified – expanding operations in the US, UK, and Austria.
  • US$300m+ in single-use technologies – including bioreactor bags for growing cells used to make personalized medicines and syringe filters for scientific research – expanding operations in the US and the UK, as well as fitting out a new facility in Cardiff, Wales.
  • US$200m+ for continuing expansion work in Cytiva and Pall Corporation’s sites across China and the rest of the Asia-Pacific region, Europe, and the US.

Shorter lead times

The funds will accelerate capacity expansion plans already underway at 13 Pall and Cytiva sites making biotechnology products for COVID-19 and other critical programs.

Production of cell culture media at Cytiva’s site in Logan, Utah is planned to double in 2023. This will be done by converting 25 000 m2 of land into new manufacturing lines, distribution hubs, and clean rooms as well as creating 250 new jobs locally. Combined with the acquisition of Intermountain Life Sciences, a manufacturer of liquid cell culture media and buffers, customers being supplied out of Logan will see shorter lead times in delivery of those products, said Cytiva.

Single use technology capacity  

As part of today’s investment, Pall said it is to expand single-use manufacturing operations in China at the site of recently acquired Austar. Plans are also underway to expand Cytiva’s partnership with Wego in China to build more single-use technology manufacturing capacity for the region.  

A new 11 000 m2 facility in Cardiff, Wales, is being fitted out to manufacture single-use bioprocessing equipment including jumper tubing assemblies, cell bags, and ÄKTA flow kits. The first products are expected to be manufactured at that site before year end, they said, and a a local hiring drive has begun to fill 250 new jobs at that site over the next two years, primarily in manufacturing, as well as warehouse operators, material handlers, and in R&D.

Resin manufacturing, membrane and filter products

The vision for the new Cytiva manufacturing facility in the US is to replicate and complement the company’s resin manufacturing capabilities at its site in Uppsala, Sweden.

The location of the new site will be announced at a later date, said Cytiva. It plans to hire 400 people in the US and Sweden over the next two years to facilitate expansion plans. 

Additionally, said Pall, its investments at sites in Newquay, UK, in Pensacola, Florida, and in San Diego, California, have increased its capacity to make and deliver membrane and filter products.

Cytiva said it has already funded a new manufacturing facility in Shrewsbury, Massachusetts, and a new cleanroom in Westborough, Massachusetts, in the US. Its new cell and gene therapy manufacturing site and center of excellence is scheduled to open in Switzerland in 2022.

Related news

Show more

Related products

Microsampling in Early Phase Drug Development

Microsampling in Early Phase Drug Development

Altasciences | 10-May-2022 | Technical / White Paper

Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic...

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Partner with Experts in Precision Medicine

Partner with Experts in Precision Medicine

CellCarta | 17-Jan-2022 | Product Brochure

At CellCarta, we’re dedicated to working with our partners to further the limitless potential of precision medicine. Our broad technology offering is designed...

Related suppliers